KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Top Cited Papers
- 15 December 2010
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (6), 594-603
- https://doi.org/10.1016/s1470-2045(10)70209-6
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Nuclear EGFR contributes to acquired resistance to cetuximabOncogene, 2009
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsClinical & Experimental Metastasis, 2008
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994